Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 6027 EDGEWOOD BEND COURT SAN DIEGO CA 92130 |
Tel: | 1-858-6177143 |
Website: | https://www.neurocrine.com |
IR: | See website |
Key People | ||
Kevin C. Gorman Chief Executive Officer, Director | Darin M. Lippoldt Chief Legal Officer, Corporate Secretary | Matthew C. Abernethy Chief Financial Officer |
Julie S. Cooke Chief Human Resource Officer | Jude Onyia Chief Scientific Officer | Eric S. Benevich Chief Commercial Officer |
David Warren Boyer Chief Corporate Affairs Officer | Ingrid Delaet Chief Regulatory Officer | Kyle W. Gano Chief Business Development and Strategy Officer | Eiry Wyn Roberts Chief Medical Officer |
Business Overview |
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights. |
Financial Overview |
For the three months ended 31 March 2024, Neurocrine Biosciences, Inc. revenues increased 23% to $515.3M. Net income totaled $43.4M vs. loss of $76.6M. Revenues reflect Collaboration revenue increase of 24% to $6.3M. Net Income reflects Acquired in-process research and develop decrease of 96% to $6M (expense), Investment income and other, net increase from $9.8M to $23.4M (income). |
Employees: | 1,448 as of Mar 31, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $13,167M as of Mar 31, 2024 |
Annual revenue (TTM): | $1,982M as of Mar 31, 2024 |
EBITDA (TTM): | $492.90M as of Mar 31, 2024 |
Net annual income (TTM): | $369.70M as of Mar 31, 2024 |
Free cash flow (TTM): | $614.40M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 100,637,227 as of Apr 25, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |